Can Maternal Autoantibodies Play an Etiological Role in ASD Development?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F20%3A00531281" target="_blank" >RIV/67985823:_____/20:00531281 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/20:10411848 RIV/00216208:11130/20:10411848 RIV/00064203:_____/20:10411848

Výsledek na webu

<a href="https://www.dovepress.com/can-maternal-autoantibodies-play-an-etiological-role-in-asd-developmen-peer-reviewed-article-NDT" target="_blank" >https://www.dovepress.com/can-maternal-autoantibodies-play-an-etiological-role-in-asd-developmen-peer-reviewed-article-NDT</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/NDT.S239504" target="_blank" >10.2147/NDT.S239504</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Can Maternal Autoantibodies Play an Etiological Role in ASD Development?

Popis výsledku v původním jazyce

Autism spectrum disorder (ASD) is a heterogeneous condition with multiple etiologies and risk factors - both genetic and environmental. Recent data demonstrate that the immune system plays an important role in prenatal brain development. Deregulation of the immune system during embryonic development can lead to neurodevelopmental changes resulting in ASD. One of the potential etiologic factors in the development of ASD has been identified as the presence of maternal autoantibodies targeting fetal brain proteins. The type of ASD associated with the presence of maternal autoantibodies has been referred to as maternal antibodies related to ASD (MAR ASD). The link between maternal autoantibodies and ASD has been demonstrated in both clinical studies and animal models, but the exact mechanism of their action in the pathogenesis of ASD has not been clarified yet. Several protein targets of ASD-related maternal autoantibodies have been identified. Here, we discuss the role of microtubule-associated proteins of the collapsin response mediator protein (CRMP) family in neurodevelopment and ASD. CRMPs have been shown to integrate multiple signaling cascades regulating neuron growth, guidance or migration. Their targeting by maternal autoantibodies could change CRMP levels or distribution in the developing nervous system, leading to defects in axon growth/guidance, cortical migration, or dendritic projection, which could play an etiological role in ASD development. In addition, we discuss the future possibilities of MAR ASD treatment.

Název v anglickém jazyce

Can Maternal Autoantibodies Play an Etiological Role in ASD Development?

Popis výsledku anglicky

Autism spectrum disorder (ASD) is a heterogeneous condition with multiple etiologies and risk factors - both genetic and environmental. Recent data demonstrate that the immune system plays an important role in prenatal brain development. Deregulation of the immune system during embryonic development can lead to neurodevelopmental changes resulting in ASD. One of the potential etiologic factors in the development of ASD has been identified as the presence of maternal autoantibodies targeting fetal brain proteins. The type of ASD associated with the presence of maternal autoantibodies has been referred to as maternal antibodies related to ASD (MAR ASD). The link between maternal autoantibodies and ASD has been demonstrated in both clinical studies and animal models, but the exact mechanism of their action in the pathogenesis of ASD has not been clarified yet. Several protein targets of ASD-related maternal autoantibodies have been identified. Here, we discuss the role of microtubule-associated proteins of the collapsin response mediator protein (CRMP) family in neurodevelopment and ASD. CRMPs have been shown to integrate multiple signaling cascades regulating neuron growth, guidance or migration. Their targeting by maternal autoantibodies could change CRMP levels or distribution in the developing nervous system, leading to defects in axon growth/guidance, cortical migration, or dendritic projection, which could play an etiological role in ASD development. In addition, we discuss the future possibilities of MAR ASD treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

<a href="/cs/project/NV18-04-00085" target="_blank" >NV18-04-00085: Význam maternálních autoprotilátek při vzniku poruch autistického spektra</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuropsychiatric Disease and Treatment

ISSN

1178-2021

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

Jun

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

8

Strana od-do

1391-1398

Kód UT WoS článku

000537737600001

EID výsledku v databázi Scopus

2-s2.0-85085978936